Financings Of The Fortnight: Can Crowdfunding Help Fill The Life Sciences Venture Gap?
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus recent news on BioTime, Lanthio, Applied Genetics Technology, and TauRx.
You may also be interested in...
Lanthio Pharma Raises €4.8 Million In Series A, Enters MorphoSys Pact
Dutch biotech Lanthio Pharma has entered into an alliance with MorphoSys to develop its lantipeptide technology, with the German drug-discovery company also participating in Lanthio Pharma’s Series A funding round.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.